Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors

Por Pal, Sumanta Kumar, Figlin, Robert A.
Publicado em 2010

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

Por Pal, Sumanta Kumar, Figlin, Robert A.
Publicado em 2011

A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy

Por Banerjee, Natasha, Sachdev, Esha, Figlin, Robert A
Publicado no Cureus (2016)

Deciphering the anticancer mechanisms of sunitinib

Por Pal, Sumanta Kumar, Figlin, Robert A, Yu, Hua
Publicado em 2010

Targeted Therapies for Non-Small Lung Cancer: An Evolving Landscape

Por Pal, Sumanta Kumar, Figlin, Robert A., Reckamp, Karen
Publicado em 2010

A New Age for Vaccine Therapy in Renal Cell Carcinoma

Por Pal, Sumanta K., Hu, Adriana, Figlin, Robert A.
Publicado em 2013

Renal cell carcinoma: An update for the practicing urologist

Por Pal, Sumanta K., Bergerot, Paulo, Figlin, Robert A.
Publicado no Asian J Urol (2015)

Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer

Por Reed, Jarred P., Devkota, Suzanne, Figlin, Robert A.
Publicado no Ann Transl Med (2019)

Renal cell carcinoma molecular targets and clinical applications, second edition /

Por Bukowski, Ronald M., Figlin, Robert A., Motzer, Robert J.
Publicado em 2009

Renal cell carcinoma translational biology, personalized medicine, and novel therapeutic targets /

Por Figlin, Robert A., Rathmell, W. Kimryn., Rini, Brian I.
Publicado em 2012

Chemokines as therapeutic targets in renal cell carcinoma

Por Reckamp, Karen L, Strieter, Robert M, Figlin, Robert A
Publicado em 2008

Tivozanib: Current status and future directions in the treatment of solid tumors

Por Pal, Sumanta K., Bergerot, Paulo G., Figlin, Robert A.
Publicado em 2012

Surveillance Strategies for Renal Cell Carcinoma Patients Following Nephrectomy

Por Chin, Arnold I, Lam, John S, Figlin, Robert A, Belldegrun, Arie S
Publicado em 2006

Akt inhibitors in clinical development for the treatment of cancer

Por Kumar Pal, Sumanta, Reckamp, Karen, Yu, Hua, Figlin, Robert A.
Publicado em 2010

Breaking through a plateau in renal cell carcinoma therapeutics: Development and incorporation of biomarkers

Por Pal, Sumanta Kumar, Kortylewski, Marcin, Yu, Hua, Figlin, Robert A.
Publicado em 2010

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma

Por Motzer, Robert J., Escudier, Bernard, Gannon, Andrew, Figlin, Robert A.
Publicado no Oncologist (2016)

Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults

Por Pal, Sumanta K., Vanderwalde, Ari, Hurria, Arti, Figlin, Robert A.
Publicado no Drugs Aging (2011)

STAT3: A Target to Enhance Antitumor Immune Response

Por Lee, Heehyoung, Pal, Sumanta Kumar, Reckamp, Karen, Figlin, Robert A., Yu, Hua
Publicado em 2011

A Comparison of Ku0063794, a Dual mTORC1 and mTORC2 Inhibitor, and Temsirolimus in Preclinical Renal Cell Carcinoma Models

Por Zhang, Hao, Berel, Dror, Wang, Yanping, Li, Ping, Bhowmick, Neil A., Figlin, Robert A., Kim, Hyung L.
Publicado em 2013

CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer

Por Reckamp, Karen L, Figlin, Robert A, Burdick, Marie D, Dubinett, Steven M, Elashoff, Robert M, Strieter, Robert M
Publicado em 2009